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Abstract 
Posterior reversible encephalopathy syndrome is a clinicoradiologic entity that may 
present with headaches, altered mental status, seizures and visual loss as well as specific 
neuroimaging findings. We report a case of a 74-year-old woman receiving adjuvant 
gemcitabine chemotherapy as monotherapy for a stage IIa pancreatic adenocarcinoma, 
who developed posterior reversible encephalopathy syndrome. 
 
Introduction 
Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity 
characterized by headaches, altered mental status, seizures, and visual loss and is 
associated with white matter vasogenic edema predominantly affecting the posterior 
occipital and parietal lobes of the brain [1–6]. 
The pathophysiology of PRES remains unclear. Two pathophysiologic mechanisms 
have been proposed regarding cerebral autoregulation: cerebral vasospasm, which results 
in cytotoxic edema [7, 8], and vasodilatation, which results in vasogenic edema [3, 9, 10]. 
The latter is more favored by most experimental and clinical data [11–15]. The 
pathophysiology of PRES also implicates endothelial dysfunctions, such as preeclampsia 
or cytotoxic therapies, especially in cases without severe hypertension [1, 16, 17].  
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Numerous factors can trigger this syndrome, the most common being acute elevation 
of blood pressure, abnormal renal function and immunosuppressive therapy [1]. Other 
possible etiologies are eclampsia [7, 18–21], lupus [22, 23], transplantation [24], neoplasia 
and chemotherapy treatment [25], systemic infections [26], and acute or chronic renal 
disease [27, 28]. 
Gemcitabine has been associated with PRES; nevertheless, the contributory effects of 
other drugs administered simultaneously with or previously to gemcitabine are not well 
clarified [29]. The purpose of this report is to present a case treated with gemcitabine as 
monotherapy. 
Case Report 
A 74-year-old woman was diagnosed with pancreatic cancer without evidence of metastasis. She 
underwent pancreaticoduodenectomy, which revealed no regional lymph node metastases or 
microscopic residual disease (T3 N0 M0). After 4 weeks, the patient was started on her first course of 
adjuvant treatment with gemcitabine (1,000 mg/m
2 on days 1, 8 and 15 of each 28-day cycle). Her 
ECOG performance status was 1. 
One day after the beginning of the third chemotherapy cycle, the patient developed severe headache. 
After a few hours, she experienced a tonic-clonic seizure and visual blurring. At that time, her blood 
pressure was 170/90 mm Hg and her creatinine level was 1.4 mg/dl (2 months before, it was 1.0 mg/dl). 
A head computed tomography was obtained, which showed mild focal hypodensity in both occipital 
lobes without any evidence of brain metastasis. In addition, a brain magnetic resonance imaging (MRI; 
T2 and fluid-attenuated inversion recovery image sequences) was performed, which revealed a 
subcortical T2 hyperintensity without enhancement, apparent on both the occipital and temporal lobes 
(fig. 1). 
The patient was treated with phenytoin and had no further seizures. After 10 days, the patient was 
asymptomatic and after 2 weeks, she underwent a follow-up brain MRI, which showed no cortical or 
subcortical T2 hyperintensity (fig. 2). 
Discussion 
The cause of PRES is not yet understood. Hypertension with failed autoregulation and 
hyperperfusion remains a popular consideration for developing brain edema [1]. The 
suggested pathophysiologic mechanisms are cerebral vasospasm with resulting ischemia 
within the involved territories and a breakdown in cerebrovascular autoregulation with 
ensuing interstitial extravasation of fluid [8]. 
The most characteristic imaging pattern in PRES is the presence of an edema involving 
the white matter of the posterior portions of both cerebral hemispheres, especially the 
parieto-occipital regions, in a relatively symmetric pattern that spares the calcarine and 
paramedian parts of the occipital lobes [1, 3, 30, 31]. However, other structures such as 
the brain stem, cerebellum, and frontal and temporal lobes may also be involved, and 
although the abnormality primarily affects the subcortical white matter, the cortex and 
the basal ganglia may also be affected [5, 32–34]. 
No single antineoplastic class or agent has been consistently associated with PRES, 
although some chemotherapeutic agents may cause direct CNS microvascular injury [35]. 
PRES is more likely to be encountered after high-dose multidrug cancer therapy, typically 
in hematopoietic malignancies [36–39].  
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Gemcitabine is a nucleoside analogue antineoplastic agent structurally similar to 
cytarabine that is approved by the US Food and Drug Administration for the use in non-
small cell lung, breast, ovarian, and pancreatic cancers [40]. It is unclear if gemcitabine 
can cross the blood-brain barrier [41]. Neurologic toxicities with gemcitabine are 
uncommon and include peripheral neuropathy and somnolence in 3 and 9% of patients, 
respectively [42]. Few data are available showing the association of PRES and 
gemcitabine. Gemcitabine-associated PRES was first identified in 2001 in the treatment of 
non-small cell carcinoma of the lung [29]. Two studies demonstrated the association of 
PRES and gemcitabine in gallbladder and pancreatic cancer treatment [35, 43]. This case 
is the first report of PRES associated with gemcitabine monotherapy in a treatment with 
adjuvant intent.  
Conclusion 
PRES is an entity not well known by neurologists and radiologists. Due to the poor 
knowledge of this syndrome, i.e. its cause and pathophysiology are not yet fully defined, it 
is sometimes not recognized. However, because of the increasing number of 
neuroimaging studies that have been conducted as well as of therapies that can induce 
PRES (which increases the number of patients treated with chemotherapy or 
immunosuppression), this phenomenon is becoming increasingly common. 
Our report demonstrates that gemcitabine per se is associated with PRES, independent 
of other drugs. 
 
 
 
 
 
 
Fig. 1. Brain MRI showing the subcortical edema in the occipital and temporal lobes. 
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Fig. 2. Brain MRI showing a reduction of the subcortical edema. 
 
 
 
 
References 
1  Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR: A 
reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500. 
2  Sheth RD, Riggs JE, Bodenstenier JB, Gutierrez AR, Ketonen LM, Ortiz OA: Parietal occipital edema in 
hypertensive encephalopathy: a pathogenic mechanism. Eur Neurol 1996;36:25–28. 
3  Hauser RA, Lacey DM, Knight MR: Hypertensive encephalopathy: magnetic resonance imaging demonstration 
of reversible cortical and white matter lesions. Arch Neurol 1988;45:1078–1083. 
4  Weingarten K, Barbut D, Filippi C, Zimmerman RD: Acute hypertensive encephalopathy: findings on spin-
echo and gradient-echo MR imaging. AJR Am J Roentgenol 1994;162:665–670. 
5  Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, Holman BL: Hypertensive 
encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 
1992;159:379–383. 
6  Fisher M, Maister B, Jacobs R: Hypertensive encephalopathy: diffuse reversible white matter CT abnormalities. 
Ann Neurol 1985;18:268–270. 
7  Lewis LK, Hinshaw DB Jr, Will AD, Hasso AN, Thompson JR: CT and angiographic correlation of severe 
neurological disease in toxemia of pregnancy. Neuroradiology 1988;30:59–64. 
8  Port JD, Beauchamp NJ Jr: Reversible intracerebral pathologic entities mediated by vascular autoregulatory 
dysfunction. Radiographics 1998;18:253–267. 
9  Strandgaard S, Paulson OB: Cerebral autoregulation. Stroke 1984;15:413–416. 
10  Nag S, Robertson DM, Dinsdale HB: Cerebral cortical changes in acute experimental hypertension: an 
ultrastructural study. Lab Invest 1977;36:150–161. 
11  Schwartz RB, Mulkern RV, Gudbjartsson H, Jolesz F: Diffusion-weighted MR imaging in hypertensive 
encephalopathy: clues to pathogenesis. Am J Neuroradiol 1998;19:859–862. 
12  Mukherjee P, McKinstry RC: Reversible posterior leukoencephalopathy syndrome: evaluation with diffusion-
tensor MR imaging. Radiology 2001;219:756–765. 
13  Schaefer PW, Buonanno FS, Gonzalez RG, Schwamm LH: Diffusion-weighted imaging discriminates between 
cytotoxic and vasogenic edema in a patient with eclampsia. Stroke 1997;28:1082–1085.  
Case Rep Oncol 2011;4:82–87 
DOI: 10.1159/000324581 
Published online: 
February 16, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
86
14  Coley SC, Porter DA, Calamante F, Chong WK, Connelly A: Quantitative MR diffusion mapping and 
cyclosporine-induced neurotoxicity. AJNR Am J Neuroradiol 1999;20:1507–1510. 
15  Ay H, Buonanno FS, Schaefer PW, Le DA, Wang B, Gonzalez RG, Koroshetz WJ: Posterior 
leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 
1998;51:1369–1376. 
16  Donaldson JO: The brain in eclampsia. Hypertens Pregnancy 1994;13:115. 
17  Roberts JM, Redman CWG: Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 
1993;341:1447–1451; erratum 1993;342:504. 
18  Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, Bravo SM, Klufas RA, Chai RY, Repke 
JT: Preeclampsia-eclampsia: clinical and neuroradiographic correlates and insights into the pathogenesis of 
hypertensive encephalopathy. Radiology 2000;217:371–376. 
19  Colosimo C Jr, Fileni A, Moschini M, Guerrini P: CT findings in eclampsia. Neuroradiology 1985;27:313–317. 
20  Naheedy MH, Biller J, Schiffer M, Azar-Kia B, Gaianopoulous J, Zarandy S: Toxemia of pregnancy: cerebral CT 
findings. J Comput Assist Tomogr 1985;9:497–501. 
21  Ishimori ML, Pressman BD, Wallace DJ, Weisman MH: Posterior reversible encephalopathy syndrome: 
another manifestation of CNS SLE? Lupus 2007;16:436–443. 
22  Punaro M, Abou-Jaoude P, Cimaz R, Ranchin B: Unusual neurologic manifestations (II): posterior reversible 
encephalopathy syndrome (PRES) in the context of juvenile systemic lupus erythematosus. Lupus 2007;16:576–
579. 
23  Baizabal-Carvallo JF, Barragán-Campos HM, Padilla-Aranda HJ, Alonso-Juarez M, Estañol B, Cantú-Brito C, 
García-Ramos G: Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin 
Neurol Neurosurg 2009;111:359–363. 
24  Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW: Posterior reversible encephalopathy syndrome 
after solid organ transplantation. AJNR Am J Neuroradiol 2008;29:924–930. 
25  Hourani R, Abboud M, Hourani M, Khalifeh H, Muwakkit S: L-asparaginase-induced posterior reversible 
encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics 
2008;39:46–50. 
26  Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J: Posterior reversible encephalopathy syndrome 
in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006;27:2179–2190. 
27  Onder AM, Lopez R, Teomete U, Francoeur D, Bhatia R, Knowbi O, Hizaji R, Chandar J, Abitbol C, Zilleruelo 
G: Posterior reversible encephalopathy syndrome in the pediatric renal population. Pediatr Nephrol 
2007;22:1921–1929. 
28  Gokce M, Dogan E, Nacitarhan S, Demirpolat G: Posterior reversible encephalopathy syndrome caused by 
hypertensive encephalopathy and acute uremia. Neurocrit Care 2006;4:133–136. 
29  Russell MT, Nassif AS, Cacayorin ED, Awwad E, Perman W, Dunphy F: Gemcitabine-associated posterior 
reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. Magn Reson Imaging 
2001;19:129–132. 
30  Duncan R, Hadley D, Bone I, Symonds EM, Worthington BS, Rubin PC: Blindness in eclampsia: CT and MR 
imaging. J Neurol Neurosurg Psychiatry 1989;52:899–902. 
31  Truwit CL, Denaro CP, Lake JR, DeMarco T: MR imaging of reversible cyclosporin A-induced neurotoxicity. 
AJNR Am J Neuroradiol 1991;12:651–659. 
32  Lamy C, Oppenheim C, Méder JF, Mas JL: Neuroimaging in posterior reversible encephalopathy syndrome. J 
Neuroimaging 2004;14:89–96. 
33  Sanders TG, Clayman DA, Sanchez-Ramos L, Vines FS, Russo L: Brain in eclampsia: MR imaging with clinical 
correlation. Radiology 1991;180:475–478. 
34  De Klippel N, Sennesael J, Lamote J, Ebinger G, de Keyser J: Cyclosporin leukoencephalopathy induced by 
intravenous lipid solution. Lancet 1992;339:1114. 
35  Rajasekhar A, George TJ Jr: Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case 
report and review of literature. Oncologist 2007;12:1332–1335. 
36  Cooney MJ, Bradley WG, Symko SC, Patel ST, Groncy PK: Hypertensive encephalopathy: complication in 
children treated for myeloproliferative disorders – report of three cases. Radiology 2000;214:711–716. 
37  Morris EB, Laningham FH, Sandlund JT, Khan RB: Posterior reversible encephalopathy syndrome in children 
with cancer. Pediatr Blood Cancer 2007;48:152–159. 
38  Sánchez-Carpintero R, Narbona J, López de Mesa R, Arbizu J, Sierrasesúmaga L: Transient posterior 
encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001;24:145–148. 
39  Pihko H, Tyni T, Virkola K, Valanne L, Sainio K, Hovi L, Saarinen UM: Transient ischemic cerebral lesions 
during induction chemotherapy for acute lymphoblastic leukemia. J Pediatr 1993;123:718–724.  
Case Rep Oncol 2011;4:82–87 
DOI: 10.1159/000324581 
Published online: 
February 16, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
87
40  Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, 
Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and 
clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized 
trial. J Clin Oncol 1997;15:2403–2413. 
41  Plunkett W, Huang P, Xu YZ, Heinemann V, Grundewald R, Gandhi V: Gemcitabine: metabolism, 
mechanisms of action, and self-potentiation. Semin Oncol 1995;22(suppl 11):3–10. 
42  Gemzar_ (gemcitabine HCl for injection) [package insert]. Indianapolis, Eli Lilly and Company, 2006. 
43  Kwon EJ, Kim SW, Kim KK, Seo HS, Kim do Y: A case of gemcitabine and cisplatin associated posterior 
reversible encephalopathy syndrome. Cancer Res Treat 2009;41:53–55. 